心房細動(Atrial Fibrillation)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Atrial Fibrillation Overview 9
Therapeutics Development 10
Pipeline Products for Atrial Fibrillation – Overview 10
Pipeline Products for Atrial Fibrillation – Comparative Analysis 11
Atrial Fibrillation – Therapeutics under Development by Companies 12
Atrial Fibrillation – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Atrial Fibrillation – Products under Development by Companies 17
Atrial Fibrillation – Companies Involved in Therapeutics Development 19
ARCA biopharma, Inc. 19
Armetheon, Inc. 20
AstraZeneca PLC 21
Bristol-Myers Squibb Company 22
Cardiome Pharma Corp 23
Daiichi Sankyo Company, Limited 24
Gilead Sciences, Inc. 25
Isis Pharmaceuticals, Inc. 26
Laboratoires Pierre Fabre SA 27
Nissan Chemical Industries, Ltd. 28
Nyken BV 29
Otsuka Holdings Co., Ltd. 30
Regado Biosciences, Inc. 31
Serodus ASA 32
Xention Limited 33
Atrial Fibrillation – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(ranolazine + dronedarone) – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Aptamers for Cardiovascular Diseases – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BMS-919373 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
bucindolol hydrochloride – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
budiodarone – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drug For Atrial Fibrillation – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
edoxaban tosylate – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
F-373280 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GsMTx-4 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ISIS-CRPRx – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NIP-151 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NYK-1112 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
OMT-33 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
OPC-108459 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ranolazine ER – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SER-102 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Block IKACh for Atrial Fibrillation – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Block Kv1.5 for Atrial Fibrillation – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules to Activate Heat Shock Protein 70 (Hsp70) for Post-Operative Atrial Fibrillation – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
vanoxerine – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
vernakalant hydrochloride – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
XEN-D0101 – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
XEN-D0103 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
XEN-R0702 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Atrial Fibrillation – Recent Pipeline Updates 78
Atrial Fibrillation – Dormant Projects 90
Atrial Fibrillation – Discontinued Products 94
Atrial Fibrillation – Product Development Milestones 95
Featured News & Press Releases 95
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 95
Nov 07, 2014: Cardiome Announces Positive Results from the BRINAVESS Asia-Pacific Phase 3 Clinical Trial 95
Nov 07, 2014: Cardiome Submits BRINAVESS Reimbursement Dossier to Italian Authorities to Support Market Access 96
Oct 31, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 96
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 97
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan 98
Sep 02, 2014: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 98
Sep 01, 2014: Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation 100
Aug 25, 2014: Cardiome Enters Commercialization Agreement With Eurolab Especialidades Medicinales For BRINAVESS In Argentina 101
Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 101
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103